Soutar RL - Search Results

1

A mutation in the c-myc-IRES leads to enhanced internal ribosome entry in multiple myeloma: a novel mechanism of oncogene de-regulation.

Chappell SA, LeQuesne JP, Paulin FE, deSchoolmeester ML, Stoneley M, Soutar RL, Ralston SH, Helfrich MH, Willis AE. Chappell SA, et al. Among authors: soutar rl. Oncogene. 2000 Sep 7;19(38):4437-40. doi: 10.1038/sj.onc.1203791. Oncogene. 2000. PMID: 10980620

2

Expression of adhesion molecules in malignant plasma cells in multiple myeloma: comparison with normal plasma cells and functional significance.

Helfrich MH, Livingston E, Franklin IM, Soutar RL. Helfrich MH, et al. Among authors: soutar rl. Blood Rev. 1997 Mar;11(1):28-38. doi: 10.1016/s0268-960x(97)90004-7. Blood Rev. 1997. PMID: 9218104 Review.

3

Pamidronate causes apoptosis of plasma cells in vivo in patients with multiple myeloma.

Gordon S, Helfrich MH, Sati HI, Greaves M, Ralston SH, Culligan DJ, Soutar RL, Rogers MJ. Gordon S, et al. Among authors: soutar rl. Br J Haematol. 2002 Nov;119(2):475-83. doi: 10.1046/j.1365-2141.2002.03824.x. Br J Haematol. 2002. PMID: 12406088 Free article.

4

Cytokine expression in multiple myeloma and monoclonal gammopathy: analysis by reverse transcription/polymerase chain reaction and quantitative PCR.

Soutar RL, Dillon JM, Brown D, Ralston SH. Soutar RL, et al. Leuk Lymphoma. 1996 Dec;24(1-2):111-20. doi: 10.3109/10428199609045719. Leuk Lymphoma. 1996. PMID: 9049967

5

Control genes for reverse-transcription-polymerase chain reaction: a comparison of beta actin and glyceraldehyde phosphate dehydrogenase.

Soutar RL, Dillon J, Ralston SH. Soutar RL, et al. Br J Haematol. 1997 Apr;97(1):247-8. Br J Haematol. 1997. PMID: 9136979 Free article. No abstract available.

6

Advances in the management of myeloma.

Hughes M, Soutar RL. Hughes M, et al. Among authors: soutar rl. Scott Med J. 2005 May;50(2):47-50. doi: 10.1177/003693300505000201. Scott Med J. 2005. PMID: 15977512 Review. No abstract available.

7

Multiple myeloma: therapeutic delivery of antibodies and aptamers.

Pujol-Navarro N, Al Qaraghuli MM, Kubiak-Ossowska K, Alsaadi MM, Horne GA, Soutar RL, Paspali E, Ferro VA, Williams MT, Mulheran PA. Pujol-Navarro N, et al. Among authors: soutar rl. Ther Deliv. 2021 Oct;12(10):705-722. doi: 10.4155/tde-2021-0041. Epub 2021 Sep 27. Ther Deliv. 2021. PMID: 34569269 Free article. Review.

8

The impact of dose escalation and resistance modulation in older patients with acute myeloid leukaemia and high risk myelodysplastic syndrome: the results of the LRF AML14 trial.

Burnett AK, Milligan D, Goldstone A, Prentice A, McMullin MF, Dennis M, Sellwood E, Pallis M, Russell N, Hills RK, Wheatley K; United Kingdom National Cancer Research Institute Haematological Oncology Study Group. Burnett AK, et al. Br J Haematol. 2009 May;145(3):318-32. doi: 10.1111/j.1365-2141.2009.07604.x. Epub 2009 Mar 8. Br J Haematol. 2009. PMID: 19291085 Free article. Clinical Trial.

9

Renal failure and multiple myeloma: pathogenesis and treatment of renal failure and management of underlying myeloma.

Clark AD, Shetty A, Soutar R. Clark AD, et al. Blood Rev. 1999 Jun;13(2):79-90. doi: 10.1016/s0268-960x(99)90014-0. Blood Rev. 1999. PMID: 10414944 Review.

10

Renal impairment at presentation in multiple myeloma continues to be associated with poor survival.

Laing AA, Geddes C, Soutar R. Laing AA, et al. Br J Haematol. 2015 Jun;169(6):901-2. doi: 10.1111/bjh.13253. Epub 2014 Dec 17. Br J Haematol. 2015. PMID: 25522297 Free article. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

69 results

Search Page

Filters